Piechota Wiesław, Krzesiński Paweł, Piotrowicz Katarzyna, Gielerak Grzegorz, Kurpaska Małgorzata, Rączka Alicja, Woźniak-Kosek Agnieszka
Department of Laboratory Diagnostics, Military Institute of Medicine, Szaserów Street 128, 04-141 Warsaw, Poland.
Department of Cardiology and Internal Diseases, Military Institute of Medicine, Szaserów Street 128, 04-141 Warsaw, Poland.
J Clin Med. 2022 Jun 16;11(12):3471. doi: 10.3390/jcm11123471.
Urine 11-dehydro-thromboxane B2 (11-dehydro-TXB2), an indirect measure of platelet activity, is elevated in cardiovascular diseases and diabetes. The purpose of our study was to determine whether urine 11-dehydro-TXB2 is elevated in aspirin-naive males with metabolic syndrome (MS) and to determine predictors of 11-dehydro-TXB2 levels. The secondary aim was to evaluate whether these MS patients could be potential candidates for the aspirin-mediated prevention of atherosclerotic cardiovascular diseases (ASCVDs). In 82 males with MS (76 hypertensive), anthropometric measures, urine 11-dehydro-TXB2, platelet count, creatinine, glucose, insulin, estimated insulin resistance, lipid parameters, high-sensitivity C-reactive protein (hs-CRP), adiponectin, homocysteine, and ten-year risk of fatal cardiovascular disease (SCORE) were assessed. Urine 11-dehydro-TXB2 levels were elevated (≥2500 pg/mg creatinine) in two-thirds of patients, including 11 high-risk patients (SCORE ≥ 5%). Homocysteine, adiponectin, hs-CRP, waist-to-hip ratio, and total cholesterol were found to be predictors of urine 11-dehydro-TXB2. In conclusion, there is a high incidence of elevated urine 11-dehydro-TXB2 in males with MS, including in some patients who are at a high or very high risk of ASCVDs. 11-dehydro-TXB2 levels are associated with hyperhomocysteinemia, inflammation, fat distribution, hypercholesterolemia, and adiponectin concentrations. Elevated 11-dehydro-TXB2 levels may support the use of personalised aspirin ASCVD prevention in high-risk males with MS. Giuseppe Patti.
尿11-脱氢血栓素B2（11-dehydro-TXB2）是血小板活性的间接指标，在心血管疾病和糖尿病患者中升高。我们研究的目的是确定未服用阿司匹林的代谢综合征（MS）男性患者的尿11-脱氢-TXB2是否升高，并确定11-脱氢-TXB2水平的预测因素。次要目的是评估这些MS患者是否可能是阿司匹林介导的预防动脉粥样硬化性心血管疾病（ASCVD）的潜在候选者。对82例MS男性患者（76例高血压患者）进行了人体测量、尿11-脱氢-TXB2、血小板计数、肌酐、血糖、胰岛素、估计胰岛素抵抗、血脂参数、高敏C反应蛋白（hs-CRP）、脂联素、同型半胱氨酸和致命性心血管疾病的十年风险（SCORE）评估。三分之二的患者尿11-脱氢-TXB2水平升高（≥2500 pg/mg肌酐），包括11例高危患者（SCORE≥5%）。发现同型半胱氨酸、脂联素、hs-CRP、腰臀比和总胆固醇是尿11-脱氢-TXB2的预测因素。总之，MS男性患者中尿11-脱氢-TXB2升高的发生率很高，包括一些处于ASCVD高风险或非常高风险的患者。11-脱氢-TXB2水平与高同型半胱氨酸血症、炎症、脂肪分布、高胆固醇血症和脂联素浓度有关。11-脱氢-TXB2水平升高可能支持在高危MS男性患者中使用个性化阿司匹林预防ASCVD。朱塞佩·帕蒂。
